Andrew Joseph Muir

Andrew Joseph Muir

Professor of Medicine

  • Hepatitis C 
  • Primary sclerosing cholangitis
  • Cirrhosis
  • Liver Transplantation
  • Clinical Trials
  • Healthcare disparities in liver disease 
  • Outcomes Research

Appointments and Affiliations

  • Professor of Medicine
  • Chief, Division of Gastroenterology in the Department of Medicine
  • Core Faculty in Innovation & Entrepreneurship
  • Member in the Duke Clinical Research Institute

Contact Information

  • Office Location: 03137B Hosp South, Durham, NC 27710
  • Office Phone: (919) 668-7193
  • Email Address: andrew.muir@duke.edu

Education

  • Duke University, 2000
  • Duke University, 1998
  • Duke University, 1997
  • Duke University, 1996
  • M.H.S. Duke University, 2001
  • M.D. Duke University, 1993

Awards, Honors, and Distinctions

  • Best Medicine Grand Rounds. Duke Department of Medicine. 2011

In the News

Representative Publications

  • Muir, AJ; Poordad, FF; McHutchison, JG; Shiffman, ML; Berg, T; Ferenci, P; Heathcote, EJ; Pawlotsky, J-M; Zeuzem, S; Reesink, HW; Dusheiko, G; Martin, EC; George, S; Kauffman, RS; Adda, N, Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response., Hepatology, vol 54 no. 5 (2011), pp. 1538-1546 [10.1002/hep.24549] [abs].
  • Muir, AJ, The protease inhibitor era: an opportunity to improve the quality of care., Dig Dis Sci, vol 56 no. 5 (2011), pp. 1252-1254 [10.1007/s10620-011-1674-2] [abs].
  • Muir, AJ; Hu, K-Q; Gordon, SC; Koury, K; Boparai, N; Noviello, S; Albrecht, JK; Sulkowski, MS; McCone, J, Hepatitis C treatment among racial and ethnic groups in the IDEAL trial., J Viral Hepat, vol 18 no. 4 (2011), pp. e134-e143 [10.1111/j.1365-2893.2010.01402.x] [abs].
  • Jou, JH; Chen, P-H; Jazwinski, A; Bouneva, I; Smith, AD; Muir, AJ, Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center., Dig Dis Sci, vol 55 no. 12 (2010), pp. 3591-3596 [10.1007/s10620-010-1366-3] [abs].
  • Muir, AJ; Shiffman, ML; Zaman, A; Yoffe, B; de la Torre, A; Flamm, S; Gordon, SC; Marotta, P; Vierling, JM; Lopez-Talavera, JC; Byrnes-Blake, K; Fontana, D; Freeman, J; Gray, T; Hausman, D; Hunder, NN; Lawitz, E, Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection., Hepatology, vol 52 no. 3 (2010), pp. 822-832 [10.1002/hep.23743] [abs].
  • McHutchison, JG; Manns, MP; Muir, AJ; Terrault, NA; Jacobson, IM; Afdhal, NH; Heathcote, EJ; Zeuzem, S; Reesink, HW; Garg, J; Bsharat, M; George, S; Kauffman, RS; Adda, N; Di Bisceglie, AM; PROVE3 Study Team,, Telaprevir for previously treated chronic HCV infection., The New England Journal of Medicine, vol 362 no. 14 (2010), pp. 1292-1303 [10.1056/NEJMoa0908014] [abs].
  • Ge, D; Fellay, J; Thompson, AJ; Simon, JS; Shianna, KV; Urban, TJ; Heinzen, EL; Qiu, P; Bertelsen, AH; Muir, AJ; Sulkowski, M; McHutchison, JG; Goldstein, DB, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance., Nature, vol 461 no. 7262 (2009), pp. 399-401 [10.1038/nature08309] [abs].
  • McHutchison, JG; Lawitz, EJ; Shiffman, ML; Muir, AJ; Galler, GW; McCone, J; Nyberg, LM; Lee, WM; Ghalib, RH; Schiff, ER; Galati, JS; Bacon, BR; Davis, MN; Mukhopadhyay, P; Koury, K; Noviello, S; Pedicone, LD; Brass, CA; Albrecht, JK; Sulkowski, MS; IDEAL Study Team,, Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection., The New England Journal of Medicine, vol 361 no. 6 (2009), pp. 580-593 [10.1056/NEJMoa0808010] [abs].
  • McHutchison, JG; Everson, GT; Gordon, SC; Jacobson, IM; Sulkowski, M; Kauffman, R; McNair, L; Alam, J; Muir, AJ; PROVE1 Study Team,, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection., The New England Journal of Medicine, vol 360 no. 18 (2009), pp. 1827-1838 [10.1056/NEJMoa0806104] [abs].
  • Lawitz, E; Rodriguez-Torres, M; Muir, AJ; Kieffer, TL; McNair, L; Khunvichai, A; McHutchison, JG, Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients., Journal of Hepatology, vol 49 no. 2 (2008), pp. 163-169 [10.1016/j.jhep.2008.03.027] [abs].
  • Jou, JH; Muir, AJ, In the clinic. Hepatitis C., Ann Intern Med, vol 148 no. 11 (2008) [10.7326/0003-4819-148-11-200806030-01006] [abs].
  • Brady, CW; Smith, AD; Stechuchak, KM; Coffman, CJ; Tuttle-Newhall, JE; Provenzale, D; Muir, AJ, Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era., Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol 14 no. 2 (2008), pp. 228-234 [10.1002/lt.21346] [abs].
  • Ramamurthy, M; Muir, AJ, Treatment of hepatitis C in special populations., Clinics in Liver Disease, vol 10 no. 4 (2006), pp. 851-865 [10.1016/j.cld.2006.08.001] [abs].
  • Patel, K; Muir, AJ; McHutchison, JG, Diagnosis and treatment of chronic hepatitis C infection., Bmj, vol 332 no. 7548 (2006), pp. 1013-1017 [10.1136/bmj.332.7548.1013] [abs].
  • Condron, SL; Heneghan, MA; Patel, K; Dev, A; McHutchison, JG; Muir, AJ, Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection., Transplantation, vol 80 no. 1 (2005), pp. 145-148 [10.1097/01.tp.0000164291.35925.7a] [abs].
  • Muir, AJ; Bornstein, JD; Killenberg, PG; Atlantic Coast Hepatitis Treatment Group,, Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites., The New England Journal of Medicine, vol 350 no. 22 (2004), pp. 2265-2271 [10.1056/NEJMoa032502] [abs].